NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Irma Bagdoniene: Extreme Lipoprotein(a) Equals Secondary Prevention Risk in FH Patients
Irma Bagdoniene/LinkedIn
Sep 22, 2025, 07:00

Irma Bagdoniene: Extreme Lipoprotein(a) Equals Secondary Prevention Risk in FH Patients

Irma Bagdoniene, Cardiologist and Lipidologist at Klinikum Lippe – University Hospital for Cardiology, Angiology, and Internal Intensive Care Medicine, posted on LinkedIn:

“This study highlights a important message: patients with extreme elevations of Lp(a) already carry a cardiovascular risk equivalent to secondary prevention — even in the primary prevention setting.

Implications for clinical practice:

  • LDL-C targets of ≤70 mg/dL, ideally ≤55 mg/dL, are fully justified.
  • Achieving these levels often requires combination therapy, including PCSK9 inhibitors.
  • These high-risk patients deserve early, intensive lipid management—not only after their first event.

A strong reminder: FH AND extreme Lp(a) is a double-hit dyslipidemia that demands aggressive and early prevention strategies.”

Title: Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia

Authors: Martine Paquette, MSca, Bertrand Cariou, MDb, Simon-Pierre Guay, MDa,c,d, Antonio Gallo, MDe, Liam R. Brunham, MDf, Sophie Béliard, MDg, Alexis Baass, MD

Irma Bagdoniene: Extreme Lipoprotein(a) Equals Secondary Prevention Risk in FH Patients

Read full article here.

Stay updated with Hemostasis Today.

Alexis Baass Angiology Antonio Gallo Bertrand Cariou Cardiology Health Hematology Hemostasis Hemostasis Today Internal Intensive Care Medicine Irma Bagdoniene Liam Brunham Lipoprotein(a) Martine Paquette Medicine Prevention Risk Simon-Pierre Guay Sophie Béliard
NewsFeed